within Pharmacolibrary.Drugs.ATC.C;

model C01DA20
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 3.0,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Organic nitrates in combination are used as antianginal agents for the treatment and prophylaxis of angina pectoris and sometimes in heart failure as vasodilators. They are often combined with other cardiovascular drugs such as beta-blockers or calcium channel blockers to enhance anti-ischemic effects. Available fixed-dose combinations may include isosorbide dinitrate with hydralazine. Their use today is approved for specific cardiovascular conditions, particularly in patients intolerant to ACE inhibitors.</p><h4>Pharmacokinetics</h4><p>There are no published clinical pharmacokinetic studies reporting parameters for fixed-dose combinations of organic nitrates corresponding to ATC C01DA20. The following are estimated parameters based on the typical pharmacokinetics of oral isosorbide dinitrate and its common combination formulations in adults with stable angina.</p><h4>References</h4><ol><li><p>Vitezic, D, &amp; Pelcic, JM (2002). Erectile dysfunction: oral pharmacotherapy options. <i>International journal of clinical pharmacology and therapeutics</i> 40(9) 393–403. DOI:<a href=&quot;https://doi.org/10.5414/cpp40393&quot;>10.5414/cpp40393</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12358156/&quot;>https://pubmed.ncbi.nlm.nih.gov/12358156</a></p></li><li><p>Kernohan, AF, et al., &amp; Reid, JL (2005). An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. <i>British journal of clinical pharmacology</i> 59(1) 85–93. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2004.02243.x&quot;>10.1111/j.1365-2125.2004.02243.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15606445/&quot;>https://pubmed.ncbi.nlm.nih.gov/15606445</a></p></li><li><p>Thadani, U, &amp; Whitsett, T (1988). Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates. <i>Clinical pharmacokinetics</i> 15(1) 32–43. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198815010-00003&quot;>10.2165/00003088-198815010-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3135973/&quot;>https://pubmed.ncbi.nlm.nih.gov/3135973</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01DA20;
